September 21, 2015.
Emerging Taiwanese biosimilars company JHL Biotech has hosted a delegation of Brazilian government officials and biotech executives in support of a partnership bid to produce affordable, world-class biosimilars. The delegation included Dr. Antonio Werneck, President of In Vitro Brazil, Dr. Augusto Raupp, President of the Research Foundation of the State of Rio de Janeiro (FAPERJ), and Mr. Tande Vieira of the Executive Group of Life Sciences of the Industrial Complex of Rio de Janeiro.
Brazil has become an increasingly attractive target for biosimilar developers, reports JHL Biotech, because of the Brazilian government's strong encouragement to its domestic manufacturers to work with international partners.
The delegation toured JHL's research and manufacturing facilities and observed its GMP production activities.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.